Dimension Research

Home
Archive
About
Long Live Radiopharmaceuticals!
Radiotherapy is an oncological mainstay. Targeted radiopharmaceuticals are sweeping the clinical landscape, but face substantial hurdles to realize…
 • 
Dimension
An Opinionated AlphaFold3 Field Guide
I break down every part of AlphaFold3 in simple-to-understand terms and give my observations and opinions along the way.
 • 
Dimension
1
Receptors Unite: Agonism with Antibodies
Virtually all FDA-approved antibodies neutralize block cell surface receptors. Why is building an activating (agonizing) antibody interesting? Why has…
 • 
Dimension
Weekend ADC Musings
Antibody-drug conjugates (ADCs) are here to stay. But how much agreement is there as to how they work, why they're more effective, and why they're more…
 • 
Dimension
NeurIPS 2023 Roundup: Drug-Target Interaction (DTI) Prediction
Data on drugs, drug targets, genetic regulatory networks, phenotypes, pathways, and more are proliferating. Pooling everything together to power DTI…
 • 
Dimension
NeurIPS 2023 Roundup: Generative Molecular Design
Similar to therapeutic proteins, NeurIPS 2023 was packed with engaged discussions around the opportunities (and pitfalls!) of generative chemistry…
 • 
Dimension
NeurIPS 2023 Roundup: Generative Protein Design
Generative protein design took center stage at NeurIPS 2023. In part one of a three part series, we highlight several papers, authors, and takeaways…
 • 
Dimension
Dimension Research
Dimension Research
Our writings focus on the interface between technology and the life sciences, including areas like—biotech platforms, software infrastructure, lab tools & instrumentation, clinical development, manufacturing & commercialization, as well as AI/ML.

Dimension Research

AboutArchiveSitemap
© 2024 Simon Barnett
Privacy ∙ Terms ∙ Collection notice
Start WritingGet the app
Substack is the home for great culture